Articles tagged "Viral therapy"

2021 American Transplant Congress
Influence of Immunosuppressant Management on Mortality in Kidney Transplant Recipients Hospitalized with COVID-19
Y. Fenig, A. Santeusanio, M. Menon, C. Liu, M. Rana, R. Shapiro
Mount Sinai Hospital, New York, NY
*Purpose: Kidney transplant recipients are thought to be at high risk for mortality from COVID-19 due to the necessity for chronic immunosuppressive therapy to prevent…
2021 American Transplant Congress
Current Practices for Management and Treatment of COVID-19 in Immunocompromised Adults: A Survey of Institutions
H. H. Nam¹, S. Aslam², O. Beaird³, G. Forrest⁴, M. Fung⁵, A. Limaye⁶, A. Multani³, J. Nelson⁷, R. Rakita⁶, L. Strasfeld⁸, J. Schaenman³
¹Medicine, University of California - Irvine, Orange, CA, ²Division of Infectious Diseases and Global Public Health, University of California - San Diego, San Diego, CA, ³Medicine, University of California - Los Angeles, Los Angeles, CA, ⁴Medicine, Rush University, Chicago, IL, ⁵Medicine, University of California - San Francisco, San Francisco, CA, ⁶Medicine, University of Washington, Seattle, WA, ⁷Medicine, Stanford University, Palo Alto, CA, ⁸Medicine, Oregon Health and Science University, Portland, OR
*Purpose: The optimal testing strategy for solid organ transplantation (SOT) donor and recipient evaluation, as well as treatment for COVID-19 is unknown. We assessed the…
2021 American Transplant Congress
Delayed Valganciclovir Initiation and the Incidence of Cytomegalovirus Infection in Liver Transplant Recipients
S. Shaikh, P. Kawewat-Ho, Y. Genyk, L. Sher, J. Kahn, L. Rivera
Keck Medical Center of USC, Los Angeles, CA
*Purpose: Opportunistic infections remain a significant burden after liver transplantation, particularly cytomegalovirus (CMV) infection. With the use of valganciclovir (VGCV), the incidence of CMV infection…
2021 American Transplant Congress
Clinical Characteristics, Risk Factors and Outcomes of Norovirus Infection in Renal Transplant Patients: A Retrospective Single Center Study
T. Brooks¹, T. Crilley¹, B. Gaglani², N. Jakharia²
¹Department of Internal Medicine, Wake Forest University Baptist Medical Center, Winston Salem, NC, ²Division of Infectious Diseases, Wake Forest University Baptist Medical Center, Winston Salem, NC
*Purpose: Norovirus gastrointestinal infection has been identified as a cause of significant morbidity among immunocompromised hosts, particularly hematopoietic stem cell transplant (HSCT) and solid organ…
2021 American Transplant Congress
Evaluation of Low Dose Famciclovir as Herpes Simplex Virus and Varicella Zoster Virus Prophylaxis in Cytomegalovirus Low Risk Solid Organ Transplant Recipients
M. Cote, A. Cubley, C. Rogers, S. Shao, C. N. Kotton
Massachusetts General Hospital, Boston, MA
*Purpose: Famciclovir is recommended for herpes simplex virus (HSV) and varicella-zoster virus (VZV) prophylaxis in cytomegalovirus (CMV) low risk (both donor and recipient CMV seronegative)…
2021 American Transplant Congress
Clinical Outcomes and Management of Covid-19 Patients Among Kidney Transplant Recipients: A Systematic Review
S. Ismail¹, A. Babonj², S. Al Harbi³, A. Babonj², A. Almalki¹, E. J. Murray⁴
¹King Khalid hospital, MNGHA, Jeddah, Saudi Arabia, ²King Abdulaziz University, Jeddah, Saudi Arabia, ³King Faisal Specialist Hospital, Jeddah, Saudi Arabia, ⁴Boston University School of Public Health, Boston, MA
*Purpose: We aim to systematically review published literature and synthesize the evidence available on therapeutic interventions and clinical outcomes used in the management of COVID-19…
2021 American Transplant Congress
Real-world Treatment Patterns of Antiviral Agents for Cytomegalovirus Among Adult Kidney Transplant Recipients: A USRDS-Medicare Linked Database Study
A. D. Raval¹, M. Ganz², P. Saravanan², Y. Tang¹, C. A. Santos³
¹Merck & Co., Inc., Kenilworth, NJ, ²Evidera, Inc., Waltham, MA, ³Rush University Medical Center, Chicago, IL
*Purpose: Cytomegalovirus (CMV) is a common viral pathogen among kidney transplant recipients (KTRs). Although guidelines recommend the use of prophylaxis or pre-emptive antiviral (AV) therapy…
2021 American Transplant Congress
Impact of Cytomegalovirus Prophylaxis on Herpes Simplex and Varicella Zoster Virus Infections in Kidney Transplant Recipients
K. Ridgely¹, B. Crowther², P. Klem², K. Schoeppler¹, K. Schwarz¹, A. Nadrash², V. Lewis¹, E. Benamu³
¹Department of Pharmacy Services, UCHealth University of Colorado Hospital, Aurora, CO, ²Ambulatory Care Pharmacy Services, UCHealth University of Colorado Hospital, Aurora, CO, ³Department of Medicine, UCHealth University of Colorado Hospital, Aurora, CO
*Purpose: To assess the impact of cytomegalovirus (CMV) targeted antiviral prophylaxis on the development of herpes simplex (HSV) and varicella zoster (VZV) infections after kidney…
2021 American Transplant Congress
Clinical Outcomes of Solid Organ Transplant Recipients Treated with Remdesivir and Convalescent Plasma for Covid-19 at the Largest Transplant Center in the United States
A. Fernandez, S. Anjan, A. Chandorkar, D. de Lima, R. Zamora, L. A. Mendez-Castaner, J. Simkins, J. Camargo, M. Morris, M. Loebe, J. Bauerlein, C. O’Brien, N. Sinha, G. Burke, G. Ciancio, A. Mattiazzi, R. Vianna, L. Abbo, G. Guerra, Y. Natori
Miami Transplant Institute, Jackson Health System, Miami, FL
*Purpose: Solid organ transplant recipients (SOTr) are at high risk for severe disease with SARS-CoV-2. Data on efficacy of potential treatment options and long-term outcomes…
2021 American Transplant Congress
Longitudinal Antibody Response and Viral Loads in Covid-infected Organ Transplant Recipients
T. M. Marinelli, V. H. Ferreira, M. Ierullo, V. Kulasingham, B. Majchrzak-Kita, C. Rotstein, S. Husain, S. Hosseini, A. Humar, D. Kumar
UHN, Toronto, ON, Canada
*Purpose: The full spectrum of COVID-19 disease and the impact of disease severity on antibody response and viral shedding dynamics in transplant patients is unclear.…